Stabilised sulforaphane for pharmaceutical development
In a significant breakthrough, a synthetic sulforaphane has been successfully stabilised in a proprietary pharmaceutical composition, extending shelf life from days to years in open air and at ambient temperature.
This novel sulforaphane-cyclodextrin complex. called Sulforadex®, is stable, orally bioavailable and has attractive cost of goods. Most importantly, Sulforadex® represents a pharmaceutical development proposition with an atypical risk profile due to the pre-existing scientific evidence relating to both the safety and efficacy of its unstable counterpart.
Bioengineered glucoraphanin for specialist nutrition markets
In association with the University of Copenhagen, Evgen is also pioneering patented state-of-the-art pathway engineering, by introducing 14 essential genes into a yeast strain, to cost effectively manufacture a “nature identical” pure glucoraphanin; one of the most promising phytochemicals for application in specialist nutrition markets.